ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer

Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.